Free Submission Public Relations &
Deutsch English


Investments Panel at Ocular Drug Discovery Meeting- March, 2014 in San Diego, CA

Print article Print article
2013-12-19 03:40:10 - Investments and Collaborations Panel at the 6th Ocular Diseases & Drug Discovery Conference on March 20-21, 2014 in San Diego, CA

GTC’s 6th Annual Ocular Diseases & Drug Discovery Conference held on March 20-21, 2014 in San Diego, CA will feature a panel discussion on Business Development, Investments and Potential for Collaborations.

The panelists include Ken Mandel, President & CEO at LayerBio; Ali Behbahani, Principal at New Enterprise Associates; Emmett Cunningham, Partner at Clarus Ventures and Patrick Johnson, Director of Business Development at Allergan.

The panel will discuss the current state of ophthalmology development and how collaborative relationships are designed. Further discussion will include topics on venture financing, environment for startups and later stage ophthalmology companies, corporate venture appetite in the ophthalmology space, areas of investment interest, IPO markets and drugs vs device investments.

The Ocular Diseases & Drug Discovery Conference continues to

promote the discovery of ocular disease by offering presentations on novel and innovative therapeutics in ocular drug development and discovery. The conference brings together leading scientists, researchers and experts to discuss and collaborate on the latest research, safety assessment, and regulatory issues. Highlights include drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other ocular diseases.

For more information, please visit

Contact Information:
GTC Conferences

Global Technology Community | 635 W. Foothill Blvd | Monrovia, CA 91016

Contact Person:
Kristen Starkey

Phone: 6262566405
email: email


Rania hafez
Phone: 626-256-6405

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact